Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Accounts Payables: 2023-2024

Historic Accounts Payables for Compass Therapeutics (CMPX) over the last 2 years, with Dec 2024 value amounting to $2.2 million.

  • Compass Therapeutics' Accounts Payables rose 222.40% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 222.40%. This contributed to the annual value of $2.2 million for FY2024, which is 45.01% down from last year.
  • As of FY2024, Compass Therapeutics' Accounts Payables stood at $2.2 million, which was down 45.01% from $4.1 million recorded in FY2023.
  • Over the past 5 years, Compass Therapeutics' Accounts Payables peaked at $4.1 million during FY2023, and registered a low of $2.2 million during FY2024.
  • For the 2-year period, Compass Therapeutics' Accounts Payables averaged around $3.2 million, with its median value being $3.2 million (2023).
  • Data for Compass Therapeutics' Accounts Payables shows a maximum YoY tumbled of 45.01% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Compass Therapeutics' Accounts Payables stood at $4.1 million in 2023, then crashed by 45.01% to $2.2 million in 2024.